Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data. Margaret Band, Clinical Trial Manager, TCTU

Size: px
Start display at page:

Download "Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data. Margaret Band, Clinical Trial Manager, TCTU"

Transcription

1 Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data Margaret Band, Clinical Trial Manager, TCTU

2 Adverse Event Reporting Monitoring of adverse events (AEs) is critical to the patient s safety and data integrity & a legal requirement The Medicines for Human Use (Clinical Trials) Regulations 2004

3 Introduction Definition of AEs Purpose of recording AEs Documenting AEs Completing and AE form description, severity, causality and outcome Reporting AEs briefly! AE SOP

4 Definition of Adverse Events AE - Adverse Event Any untoward medical occurrence or the deterioration of a preexisting medical condition in a subject in a clinical trial An AE does not necessarily have to have a causal relationship with the study treatment / procedure An AE can therefore be any unfavourable and unintended sign (eg. tachycardia) including laboratory findings which are clinically significant, symptom (eg. nausea, chest pain) or a disease The term AE is used to include both serious and non-serious AEs Elective hospitalisations for pre-treatment conditions are not AEs

5 Definition of Adverse Events AR - Adverse Reaction An adverse reaction (AR) is where it is suspected that an AE has been caused by a reaction to a trial drug The reaction may be a known side effect of the medication (AR) or it may be a new previously unrecognized adverse reaction (UAR) UAR - Unexpected Adverse Reaction An AR wich is not described in Investigator s Brochure (IB) or Summery of Product Characteristics (SmPC) Not all AEs are ARs but all ARs are AEs

6 Serious Adverse Events All SAEs are AEs not all AEs are SAEs Usually any AE, AR or UAR that at any dose: results in death; is life threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe); requires hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect. is considered a SAE. However

7 Serious Adverse Events The reporting of SAEs can be excluded if documented in the study protocol. The exclusion of reporting some SAEs may be due to their expected occurrence in the population and disease under investigation These should be recorded in the AE log but no SAE form required.

8 Purpose of recording Adverse Events Legal requirement - The Medicines for Human Use (Clinical Trials) Regulations 2004 Safety Signals Informs Data Monitoring Committee safeguard the interests of trial participants assess the safety and efficacy of the interventions during the trial monitor the overall conduct of the clinical trial Accuracy in diagnosis is important for detection and evaluation of safety signals

9 Purpose of recording Adverse Events Regulatory authorities want to see if a drug trial follows reported side effect profiles as reported in the Investigators Brochure and Summary of Product Characteristics New drugs have to build up this profile in clinical trials AE analysis must count side effects for each treatment arm Companies must keep track of the side effect profile of their drugs

10 Coding of Clinical Trial Data Most data entered on Case Report Forms are coded in some form Some coding is performed by investigators at point of data entry For example, numeric codes for severity of adverse event: 1= mild, 2= moderate, etc. Coding of free text data, as provided in an AE Log, is performed after data collection, free text is otherwise not analyzable Coding AEs allows free text to be grouped into meaningful categories for analysis to quantify AEs for a particular study Most research organisations will use a specific coding mechanism to ensure consistency of coding TCTU uses MedDRA - Medical Dictionary for Regulatory Activities Accuracy of coding determines accuracy of analysis

11 Coding Challenges Some reported AEs! Not from TCTU! Went to hell Recurrent fatal stroke Hears New Age music when the furnace turns on LK RTCTL UNSP XTRNDL Charcoal-like, gritty granules in his underwear Can t control patient during menses His nodule is sticking out Normally normal after drinking coffee Died of cancer of the placebo Superior members fornication Barely visible posterior Seeing people in room, seeing chickens at window Seeing stars and chicken farting Patient recently began new job where he works around chicken wings and barbecue sauce

12 Documenting Adverse Events AE log Medical notes

13 Includes: Date of onset Description Severity Causality Action Outcome End date The Adverse Event Log

14 Adverse Event Log

15 Date of Onset Date event started not date first reported to investigator.

16 Description of AE Benefits of Quality Data Generating Quality Data Coding of Clinical Trial Data Symptom vs Syndrome Problems with Coding Data

17 Benefits of Quality Data Accurate and timely information on issues that affect conduct of clinical trial and affect patient safety Improved communication among sponsors, investigators, and regulatory agencies about medicinal products Aids in safety signal detection and evaluation Ensures accuracy of information about the product including investigators brochures and prescribing information Benefits medical professionals Benefits patients

18 Generating Quality Data Clear Concise Complete Accurate Be specific if possible - Headache - more than 50 types, including cluster, sinus, migraine, lumbar puncture headache Organisms - down to species level e.g. Staphylococcus aureus

19 Symptom vs Diagnosis Where possible, report the most important medical event or specific diagnosis rather than individual signs and symptoms Can provide provisional diagnosis e.g. possible, presumed, rule out Diagnosis should not be assumed by Research Nurse Accuracy is important in preventing dilution of safety signals or generating Signs and symptoms false signals chest pain, breathlessness, sweating, ECG changes Diagnosis Myocardial infarction E.g. Report AE as Myocardial Infarction

20 Problems with coding data Appropriate coding requires clear initial data What is clear to the investigator at the point of data entry may be unclear to the coder at the point of data coding Sponsor must only code reported verbatim term; not permitted to interpret or draw information from other sources

21 Generating Quality Data Avoid: Ambiguous information Congestion (nasal, liver, sinus, pulmonary?) Cramp (muscle, menstrual, abdominal?) Pain (where?) Ambiguous abbreviations MI (myocardial infarction or mitral incompetence?) GU pain (gastric ulcer pain or genito-urinary pain?) Decreased BS (breath sounds, bowel sounds or blood sugar?) Exercise caution with abbreviations that could be misinterpreted Vague information Patient felt fuzzy, weird, experienced every adverse event

22 Generating Quality Data Try to use accepted medical terminology Give specific information Non-specific information Oedema (coded as oedema) Left wrist oedema (coded as Peripheral oedema) More specific - Injection site oedema left wrist (coded as Injection site oedema)

23 Generating Quality Data Death, hospitalization, investigations and disability are outcomes and are not usually considered to be adverse events Provide details of the underlying event, if known Examples: Death due to myocardial infarction (Coded as Myocardial infarction with death captured as the outcome) Hospitalization due to congestive heart failure (Coded as Congestive heart failure with hospitalization captured as the outcome)

24 Generating Quality Data Recording laboratory data Ambiguous laboratory data Glucose of 40 (Source of specimen - blood, urine, CSF? What units?) Would have to code as Glucose abnormal if additional clarification is not obtained Conflicting laboratory data Hyperkalemia with serum potassium of 1.6 meq/l Would have to code as Serum potassium abnormal If using numeric values, provide units and reference range. Be specific about specimen source and diagnostic result/clinical diagnosis.

25 Generating Quality Data Try to avoid combination terms - these will have to be split into individual terms Combination terms Diarrhoea, nausea and vomiting Should be recorded as: Diarrhoea Nausea Vomiting

26 Generating Quality Data Falls: a fall in it s self is not an AE however, If a patient hurts themselves record any injury as AE Fractured right wrist due to fall If an underlying cause is present record cause as AE Postural hypotension resulting in fall

27 Assessing severity MUST be assessed by medically qualified person on delegation log (legal requirement) Mild- awareness of sign or symptom, but easily tolerated Moderate- discomfort sufficient to cause interference with normal activities Severe- incapacitating with inability to perform normal activities Severe is not the same as serious!

28 Assessing Causality MUST be assessed by medically qualified person on delegation log (legal requirement) Unrelated - not considered to be related to study drug/intervention, other cause is more probable. Possibly although a relationship to study drug/intervention cannot be completely ruled out other explanations are more likely Probably - good reason and evidence for relationship to study drug/intervention and absence of a more likely explanation Definitely the known effects of the study drug/intervention or challenge testing suggest the study drug/intervention is the most likely cause.

29 Action taken Action to the study drug/intervention e.g. stopped, dose reduced Other medication started/stopped/dose change Other treatment required e.g. physio Hospitalisation Remember: if study drug/intervention stopped or reduced this should be recorded in the CRF any action to other medication, started/stopped/dose change, should also be recorded in the Concomitant Medications Log

30 Outcome Resolved date Ongoing - all AEs should be followed up to resolution or end of study Resolved with seaquelae disability or incapacity Death date

31 Up Dating AE Logs All AEs should be followed up until resolution or end of study Unless resolved every AE should be reviewed at each visit Assess if still ongoing or now resolved Assess if action taken has been changed Assess if diagnosis has been made/changed Correct AE if necessary E.g. Chest pain now been diagnosed as angina: change AE to angina (remember to sign and date changes on paper CRF and update OpenClinica/data management system) If several AEs now have one diagnosis change first AE to new diagnosis and score through additional AEs (update data management system) E.g. Separate AEs of diarrhoea and vomiting now diagnosed as Gastroenteritis : change diarrhoea to Gastroenteritis score through vomiting AE. The patient now has only one AE Gastroenteritis. At end of study ensure all AEs are either resolved (give end date) or ticked as ongoing (e.g new diagnosis of diabetes)

32 Up Dating AE Logs example

33 Medical Notes All AEs reported by the patient should be documented in the patient s medical notes If any action has been taken by the study team this should be recorded GP should be informed if it is felt necessary, ask the patient s permission Medical notes can be used as source data for AEs

34 Reporting AEs to Sponsor Complete CRF and enter in OpenClinica/data management system in timely manner Data used to inform Data Monitoring Committee

35 AE SOP TASC SOP 11: Identifying, Recording and Reporting Adverse Events for Clinical Trials of Investigational Medicinal Products

MedDRA Coding Quality: How to Avoid Common Pitfalls

MedDRA Coding Quality: How to Avoid Common Pitfalls MedDRA Coding Quality: How to Avoid Common Pitfalls Patricia Mozzicato, MD Chief Medical Officer MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides are those of

More information

DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]

DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD] SCREENING Visit Date: DEMOGRAPHICS / / [YYYY/MM/DD] Consent Signed Date and time / / [YYYY/MM/DD] : Has written assent been obtained? If no, why not? YES NO Gender: Male Female Birthdate: Permission given

More information

Adverse Experience Reporting

Adverse Experience Reporting Managing and reporting adverse events Key learning objectives By the end of this session, you will be able to: Define and classify an adverse event; Differentiate between serious and severe adverse events;

More information

PHARMACOVIGILANCE GLOSSARY

PHARMACOVIGILANCE GLOSSARY PHARMACOVIGILANCE GLOSSARY Section 1 Section 2 Section 3 Section 4 Definitions of terminology used for side effects Definitions of drug safety terms Definitions of risk terminology Definitions of general

More information

Adverse Event Reporting. Good Clinical Practice

Adverse Event Reporting. Good Clinical Practice Adverse Event Reporting Good Clinical Practice Definitions and IMP Information The Elfin Dossier describes the physical and chemical, toxicological pharmacological data on an IMP No overt toxicity is expected

More information

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2): Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS

More information

Understanding Adverse Events

Understanding Adverse Events The Fundamentals of International Clinical Research Workshop Understanding Adverse Events Deborah Hilgenberg Family Health International Goals of the Presentation Definition of Adverse Event (AE) Definitions

More information

WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS

WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Adverse Events in Clinical Trials: Definitions and Documentation May 2016 Objectives Recognize the

More information

Safety Assessment in Clinical Trials and Beyond

Safety Assessment in Clinical Trials and Beyond Safety Assessment in Clinical Trials and Beyond Yuliya Yasinskaya, MD Medical Team Leader Division of Anti-Infective Products Center for Drug Evaluation and Research FDA Clinical Investigator Training

More information

Research & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff

Research & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff Department Title of SOP Research & Development Safety reporting SOP SOP reference no: R&D GCP SOP 07 Authors: Current version number and date: J H Pacynko and J Illingworth Version 9, 31.01.18 Next review

More information

8.0 ADVERSE EVENT HANDLING

8.0 ADVERSE EVENT HANDLING 8.0 ADVERSE EVENT HANDLING In accordance with the U.S. Code of Federal Regulations governing IND safety reports (Code of Federal Regulations 21, 312.32), adverse events (AEs) are reported from research

More information

Serious Adverse Event (SAE) Form Clinical Trials

Serious Adverse Event (SAE) Form Clinical Trials Protocol Code number: LP0162-1325 1. Trial information: Subject ID: Site No.: Country: If blinded trial, was the study treatment unblinded? Yes No Is this the initial report of an SAE or a follow-up? Initial

More information

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB

More information

CTCAE & Source Documentation. Elizabeth Ness, RN, MS Director, Office of Education and Compliance Center for Cancer Research

CTCAE & Source Documentation. Elizabeth Ness, RN, MS Director, Office of Education and Compliance Center for Cancer Research CTCAE & Source Documentation Elizabeth Ness, RN, MS Director, Office of Education and Compliance Center for Cancer Research Agenda 1.Definition of AE 2.AE standards 3.AE documentation 4.AE and data quality

More information

Serious Adverse Event (SAE) Form Clinical Trials

Serious Adverse Event (SAE) Form Clinical Trials Protocol Code number: LP0162-1334 1. Trial information: Subject ID: Site No.: Country: Is this the initial report of an SAE or a follow-up? Initial Follow-up, follow up no. In which period of the trial

More information

ADVERSE EVENT REPORTING. Catherine Dillon, CCRP

ADVERSE EVENT REPORTING. Catherine Dillon, CCRP ADVERSE EVENT REPORTING Catherine Dillon, CCRP Reporting Adverse Events Adverse Events (AEs) are... any untoward medical occurrence in a subject that was not previously identified which does not necessarily

More information

SAE håndtering i protokol CC MM-001

SAE håndtering i protokol CC MM-001 SAE håndtering i protokol CC-92480-MM-001 An SAE is any AE occurring at any dose that: Results in death; Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate risk of

More information

STANDARD OPERATING PROCEDURE

STANDARD OPERATING PROCEDURE Research Department STANDARD OPERATING PROCEDURE SOP Number C117 Version Number 2.1 Effective Date 01 Sept 2018 Author Angela Pinder Related SOPs C108: Sponsorship C109: Code Break C118: Risk Assessment

More information

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 January 2010 Version 2.0 Table of Contents 1. INTRODUCTION...1 1.1 Scope... 1 1.2 Purpose... 1 1.3 Responsibilities...

More information

SAFETY AND EFFICACY ASSESSMENTS

SAFETY AND EFFICACY ASSESSMENTS SAFETY AND EFFICACY ASSESSMENTS The observations and procedures described in (Primary Arthritis Assessments) and the Hip or Knee Pain on motion assessment described in (Secondary Arthritis Assessment)

More information

Adverse Event Monitoring and Reporting

Adverse Event Monitoring and Reporting Adverse Event Monitoring and Reporting MTN 005 Study-Specific Training SSP Section 11 AE Definition The International Conference on Harmonization Consolidated Guidance for Good Clinical Practice (ICH-E2A)

More information

Medical Questionnaire

Medical Questionnaire MEDICIS Health Testing Center Avenue de Tervueren 236 115 Bruxelles Tel : 2/762.5.44 Medical Questionnaire Name :. Maiden name : First name :. Sex :. Address :...... Phone (private) : Office :. Date of

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Serious Adverse Event Report Form (CTIMP)

Serious Adverse Event Report Form (CTIMP) SAE Identifier: Serious Adverse Event Report Form (CTIMP) Form completion instructions overleaf 1. Report type (tick one) Initial report Follow-up information 2. Site name: 3. Participant details Study

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Unanticipated Problems and Adverse Events

Unanticipated Problems and Adverse Events Unanticipated Problems and Adverse Events David Borasky, MPH, CIP Office of Research Protections RTI International Research Triangle Park, North Carolina, USA Introduction IEC review of unanticipated problems

More information

AE Toxicity Grading for Transplant Patients

AE Toxicity Grading for Transplant Patients AE Toxicity Grading for Transplant Patients Marcie Tomblyn, MD, MS Associate Member Director, BMT Clinical Research Moffitt Cancer Center Objectives Why do we care????? Toxicity vs Adverse Event vs Serious

More information

Medical condition SELF Mother Father Sibling (list brother or sister) Anxiety Bipolar disorder Heart Disease Depression Diabetes High Cholesterol

Medical condition SELF Mother Father Sibling (list brother or sister) Anxiety Bipolar disorder Heart Disease Depression Diabetes High Cholesterol PRE-EVALUATION FORM Medical condition SELF Mother Father Sibling (list brother or sister) Anxiety Bipolar disorder Heart Disease Depression Diabetes High Cholesterol High Blood Pressure Obesity Heart Defect

More information

Present-on-Admission (POA) Coding

Present-on-Admission (POA) Coding 1 Present-on-Admission (POA) Coding Michael Pine, MD, MBA Michael Pine and Associates, Inc 2 POA and Coding Guidelines (1) Unless otherwise specified, a POA modifier must be assigned to each principal

More information

Adverse events following Immunisation Common and Uncommon. Dr Anna Clarke National Immunisation Office September

Adverse events following Immunisation Common and Uncommon. Dr Anna Clarke National Immunisation Office September Adverse events following Immunisation Common and Uncommon Dr Anna Clarke National Immunisation Office September 2016 www.immunisation.ie Abbreviations ADR-adverse drug reaction AE- adverse event AEFI-adverse

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HEALTH INFORMATION FORM

HEALTH INFORMATION FORM #102, 506-71 Ave SW Calgary AB T2V 4V4 Ph 587.352.9199 Fax 1.888.501.1724 info@fullcirclecalgary.ca www.fullcirclecalgary.ca Part 1: BASIC INFORMATION HEALTH INFORMATION FORM Name: Date: Address: City:

More information

MedDRA Coding and Versioning

MedDRA Coding and Versioning MedDRA Coding and Versioning 4th ANNUAL INNOVATIONS IN CLINICAL DATA MANAGEMENT Alexandria, VA. 27-28 October 2016 Anna Zhao-Wong, MD, PhD Deputy Director of MedDRA MSSO anna.zhao-wong@meddra.org Agenda

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Adverse Events- Love them, hate them, report them!

Adverse Events- Love them, hate them, report them! Adverse Events- Love them, hate them, report them! Billi Tatum, RN, CCRC Regional Vascular Center Harborview Medical Center and the University of Washington Medical Center Objectives Define and identify

More information

Safety Manual: DAD Trial

Safety Manual: DAD Trial Safety Manual: DAD Trial Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial Short title: Diabetes and Depression

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT CIOMS FORM SUSPECT ADVERSE REACTION REPORT DE-BFARM-17152663 I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 4-6 REACTION ONSET privacy (10002948): Aphasia ] linkshemisph.

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.13 Based on MedDRA Version 20.0 1 March 2017 Disclaimer and Copyright Notice This document is protected by copyright

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Schizophrenia Schizophrenia is a mental illness with a number of symptoms, including confused or unclear thinking and speech,

More information

Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA

Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA 98136 206.200.3595 Today s date Name Legal name (if different) Phone (primary) (secondary) Address City State Zip Email

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.4 Based on MedDRA Version 15.1 1 October 2012 Disclaimer and Copyright Notice This document is protected by copyright

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

MEDICAL DIRECTIVE Title: Administration of Nicotine Replacement Therapy by Health Professionals at Pinewood Centre of Lakeridge Health

MEDICAL DIRECTIVE Title: Administration of Nicotine Replacement Therapy by Health Professionals at Pinewood Centre of Lakeridge Health Approved by/date: Medical Advisory Comm. Mar 25, 2014 Authorizing physician(s)/nurse practitioner Dr Eli Sagi, Chief of Psychiatry, Medical Director, Mental Health and Pinewood Centre Dr. Ihab Sorial,

More information

SYNOPSIS. Date 15 June 2004

SYNOPSIS. Date 15 June 2004 Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label

More information

Medical CCRN. Critical Care Register Nurse. Download Full Version :

Medical CCRN. Critical Care Register Nurse. Download Full Version : Medical CCRN Critical Care Register Nurse Download Full Version : https://killexams.com/pass4sure/exam-detail/ccrn Answer: D Section 20: Sec Twenty (351 to 355) Details:Critical Care Nursing Neonatal Exam

More information

2:39 2: Dizziness and nausea Cerebral. 2:57 1: Vomiting Gastro-intestinal

2:39 2: Dizziness and nausea Cerebral. 2:57 1: Vomiting Gastro-intestinal Supplemental: Table B: Detailed description of adverse events by time, treatment group and procedure T-spinal to incident T-spinal to PACU discharge Group THA/TKA Adverse event description Adverse event

More information

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation

More information

Clinical Trial Synopsis TL-OPI-516, NCT#

Clinical Trial Synopsis TL-OPI-516, NCT# Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus

More information

Chantix Label Update 2018

Chantix Label Update 2018 Chantix Label Update 2018 Chantix (varenicline) Prescribing Information Chantix Prescribing Info URL and Disclaimer Please refer to the full Prescribing Information on important treatment considerations

More information

New Patient Packet. Patient Name: DOB: Age: Address: City: State: Zip: Address: City: State: Zip: Name: Address: Phone: Fax:

New Patient Packet. Patient Name: DOB: Age: Address: City: State: Zip: Address: City: State: Zip: Name: Address: Phone: Fax: New Patient Packet Patient Name: DOB: Age: Sex: Male / Female Height: Weight: PHYSICIAN CARE Primary Care Physician: Address: City: State: Zip: Phone: Fax: Referring Physician (if different from PCP):

More information

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care Page 1 of 7 Patient Demographics First Name* Last Name* Date Of Birth* Home Phone* Mobile Phone Phone Gender* Email Preferred Communication Street Address 1* Street Addresss 2 Zip* City* State* Emergency

More information

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1. RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion

More information

J O B A I D S. for MANAGING ADVERSE EVENTS FOLLOWING MASS DRUG ADMINISTRATION (AEs-f-MDA) and S E R I O U S A D V E R S E E V E N T S ( S A E s )

J O B A I D S. for MANAGING ADVERSE EVENTS FOLLOWING MASS DRUG ADMINISTRATION (AEs-f-MDA) and S E R I O U S A D V E R S E E V E N T S ( S A E s ) J O B A I D S for MANAGING ADVERSE EVENTS FOLLOWING MASS DRUG ADMINISTRATION (AEs-f-MDA) and S E R I O U S A D V E R S E E V E N T S ( S A E s ) This Job Aid was developed by RTI International as part

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Elements for a public summary. VI.2.1 Overview of disease epidemiology

Elements for a public summary. VI.2.1 Overview of disease epidemiology VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Coronary artery disease and as anticoagulant (inhibiting the clotting of the blood) in patients undergoing surgery to treat blockages

More information

HEALTH INFORMATION FORM

HEALTH INFORMATION FORM #102, 506-71 Ave SW Calgary AB T2V 4V4 Ph 587.352.9199 Fax 1.888.501.1724 info@fullcirclecalgary.ca www.fullcirclecalgary.ca Part 1: BASIC INFORMATION HEALTH INFORMATION FORM Name: Date: Address: City:

More information

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased

More information

Adverse Events Following. Kevin Connolly Waterford, Aug. 25, 2016

Adverse Events Following. Kevin Connolly Waterford, Aug. 25, 2016 Adverse Events Following Immunisation Kevin Connolly Waterford, Aug. 25, 2016 Abbreviations ADR adverse drug reaction AE adverse event AEFI adverse event following immunisation SAE serious adverse event

More information

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy Assessment Prior to administration: Assess patient for chest pain, dysrhythmias, and vital signs (initially and throughout therapy) Obtain complete medical history, including allergies, especially heart

More information

STANDARD OPERATING PROCEDURE

STANDARD OPERATING PROCEDURE Research Department STANDARD OPERATING PROCEDURE SOP Number C117 Version Number 1.3 Effective Date Author Anna Leesley Angela Pinder Related SOPs C108: Sponsorship C109: Code Break B131: Monitoring of

More information

cardiovascular events when in use in these indications and the outcome of the review is summarised below.

cardiovascular events when in use in these indications and the outcome of the review is summarised below. Annex II Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation

More information

INFLECTRA Infliximab Infusion 1,2 & 3

INFLECTRA Infliximab Infusion 1,2 & 3 DEPARTMENT OF RHEUMATOLOGY DAY CASE ADMISSION RECORD PATIENT DAY CASE BOOKING REQUEST To be completed by Consultant, Registrar requesting day case Admission Hospital No. Surname Forename Address INFLECTRA

More information

Who is filling out this intake form? Self Spouse Parent Guardian

Who is filling out this intake form? Self Spouse Parent Guardian Office Use Only: Reviewed with Patient Data Entry Scan & File Date: Date: Date: Initials: Initials: Initials: Today s Date: Who is filling out this intake form? Self Spouse Parent Guardian If you are not

More information

Circulation and Cardiac Emergencies. Emergency Medical Response

Circulation and Cardiac Emergencies. Emergency Medical Response Circulation and Cardiac Emergencies Lesson 19: The Circulatory System and Cardiac Emergencies You Are the Emergency Medical Responder You are called to the home of a 50-year-old man whose wife called 9-1-1

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.10 Based on MedDRA Version 11.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical and Social History

More information

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment

More information

Safinamide (Addendum to Commission A15-18) 1

Safinamide (Addendum to Commission A15-18) 1 IQWiG Reports Commission No. A15-41 Safinamide (Addendum to Commission A15-18) 1 Addendum Commission:A15-41 Version: 1.1 Status: 29 October 2015 1 Translation of addendum A15-41 Safinamid (Addendum zum

More information

Goal of site data management 12/2/2009. Ultimate goal: reliable and valid clinical trial to improve health

Goal of site data management 12/2/2009. Ultimate goal: reliable and valid clinical trial to improve health RC-4 Overview of Clinical Site Operations and Management Unit 4: Overview of Data Quality and Monitoring Principal Investigators Lynda Wilson, PhD, RN Marti Rice, PhD, RN Program Manager TBA Course Instructors:

More information

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D. Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is

More information

A randomised controlled study of epidural fentanyl analgesia following lumbar laminectomy

A randomised controlled study of epidural fentanyl analgesia following lumbar laminectomy A randomised controlled study of epidural fentanyl analgesia following lumbar laminectomy Mr. S Thomson 1 Mr. P Mitchell 3 Mr. PT van Hille 2 Dr. B Gregson 3 1. Department of Neurosurgery, Cambridge University

More information

Your treatment with XELJANZ

Your treatment with XELJANZ Your treatment with XELJANZ (tofacitinib citrate) THIS BROCHURE HAS BEEN PRODUCED FOR PATIENTS WHO HAVE BEEN PRESCRIBED XELJANZ. BEFORE USING XELJANZ, PLEASE REVIEW THE PACKAGE LEAFLET FOR THIS MEDICINAL

More information

Gemcitabine and carboplatin (Lung)

Gemcitabine and carboplatin (Lung) Gemcitabine and carboplatin (Lung) Gemcitabine and carboplatin (Lung) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may

More information

Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge

Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge What is a venous thromboembolism (VTE)? This is a medical term that describes a blood clot that develops in a deep vein

More information

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013 MedDRA Coding/ AE Log Item 1 Refresher ASPIRE Protocol Team Meeting February 10, 2013 MedDRA Coding Overview MedDRA: standardized dictionary of medical terminology Results from ICH initiative to standardize

More information

GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS. Version 1 (reviewed unchanged January 2018)

GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS. Version 1 (reviewed unchanged January 2018) GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS Version 1 (reviewed unchanged January 2018) RATIFYING COMMITTEE Drugs and Therapeutics Group DATE ORIGINALLY 29 th October2014

More information

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary- The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM 10% [100 mg/ml] is available in single use bottles of 20 ml, 50 ml, 100

More information

SUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA

SUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA SUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA Active Substance: Anatomical Therapeutic Code: MAH or Applicant: Medicinal Product(s) to Which this RMP Refers: Products Concerned (Brand Names): Patiromer

More information

Please fill out the following form in as much detail as possible. Please Print. Name. Address. City State Zip. Home Phone Office Phone.

Please fill out the following form in as much detail as possible. Please Print. Name. Address. City State Zip. Home Phone Office Phone. CASE NO. Please fill out the following form in as much detail as possible. Please Print Date Name Address City State Zip Home Phone Office Phone E-mail Address Age Date of Birth Occupation Sex (M) (F)

More information

PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS:

PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS: 1 NAME: DATE OF BIRTH PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS: PAST MEDICAL HISTORY (YOUR MEDICAL HISTORY) :

More information

J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health

J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health Patient Clinical Information Questionnaire 1.0 Date of Questionnaire Completion; / / 2.0 Patient Data 2.1 Name:

More information

Managing your Diabetes when you are Sick. Type 1 Diabetes

Managing your Diabetes when you are Sick. Type 1 Diabetes Managing your Diabetes when you are Sick Type 1 Diabetes Disclaimer This is general information developed by The Ottawa Hospital. It is not intended to replace the advice of a qualified health-care provider.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Adverse Events Following Immunisation

Adverse Events Following Immunisation Adverse Events Following Immunisation (common, uncommon, shockin rare, and how do we know their likely cause?) Kevin Connolly Portiuncula Hospital, Sept. 18, 2017 Definitions Adverse Event (AE).. untoward

More information

MEDICAL QUESTIONNAIRE (male)

MEDICAL QUESTIONNAIRE (male) MEDICAL QUESTIONNAIRE (male) Slievemore Clinic, Old Dublin Road, Stillorgan, Co. Dublin. Tel 01-2000501/502 Fax: 01 2780248 The appointment comprises of a discussion about this questionnaire and a subsequent

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Emory Clinic Department of Neurological Surgery Second Opinion Questionnaire

Emory Clinic Department of Neurological Surgery Second Opinion Questionnaire Emory Clinic Department of Neurological Surgery Second Opinion Questionnaire First Name: M.I. Last Name: Date of Birth: Phone: Marital Status: Married Divorced Separated Widowed Single Work Status: Employed

More information

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309

More information

þ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION

þ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION CIOMS FORM SUSPECT ADVERSE REACTION REPORT DE-BFARM-17182698 I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 4-6 REACTION ONSET privacy DE DA MO YR [ MedDRA 20.0

More information

The only biologic approved to treat SLE: now with multiple delivery options

The only biologic approved to treat SLE: now with multiple delivery options The only biologic approved to treat SLE: now with multiple delivery options BENLYSTA (belimumab) Autoinjector SC Prefilled syringe IV Intravenous infusion Consider the options: visit Belimumab.com INDICATION

More information

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT CIOMS FORM SUSPECT ADVERSE REACTION REPORT DE-BFARM-17359392 I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 4-6 REACTION ONSET privacy DE [ MedDRA 20.0 LLT (10013968):

More information

PATIENT MEDICAL HISTORY FOR B.O.L.D. (Please check the most appropriate answer. If you have any questions please call the office for assistance)

PATIENT MEDICAL HISTORY FOR B.O.L.D. (Please check the most appropriate answer. If you have any questions please call the office for assistance) Name: Date of Birth: Date: Race: Caucasion African American Hispanic Native American Pacific Islander PATIENT MEDICAL HISTORY FOR B.O.L.D. (Please check the most appropriate answer. If you have any questions

More information

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT CIOMS FORM SUSPECT ADVERSE REACTION REPORT DE-BFARM-17170175 I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 4-6 REACTION ONSET privacy starke Rötung der Wangen

More information

Adverse Event Reports and Dietary Supplements

Adverse Event Reports and Dietary Supplements Adverse Event Reports and Dietary Supplements Supply Side East April 28, 2010 Michael McGuffin President, American Herbal Products Association mmcguffin@ahpa.org DS & OTC * Consumer Protection Act Sponsors:

More information